Authorities File Bribery Charges Against Senior Officials Of Pharma Company And SFDA
This article was originally published in PharmAsia News
Executive Summary
Chen Haifeng, head of China's State FDA's Center for Drug Evaluation and Gu Lijun, pharma company general manager, were taken to court for alleged bribery and corruption to the tune of RMB 1.3 million between 2004-2007 for fast drug registration approvals